Featured Research

from universities, journals, and other organizations

Monoclonal Antibodies -- The Gentle Cure For Cancer?

Date:
December 2, 1997
Source:
British Society Of Immunologists
Summary:
One of the most exciting discoveries for medical science was how to produce, in the lab, many antibodies responding to a single antigen. These so-called monoclonal antibodies have found many uses in modern medicine, including the diagnosis of cancer. Dr Martin Glennie, from the Tenovus Research Laboratory, Southampton, UK, thinks monoclonal antibodies (mAbs) could be used in the treatment of cancer too.

When the immune system responds to disease it produces many different antibodies against different viral or bacterial proteins (antigens). One of the most exciting discoveries for medical science was how to produce, in the lab, many antibodies responding to a single antigen. These so-called monoclonal antibodies have found many uses in modern medicine, including the diagnosis of cancer. At the British Society for Immunology Annual Congress in Brighton this week Dr Martin Glennie, from the Tenovus Research Laboratory, Southampton, UK, will explain how he thinks monoclonal antibodies (mAbs) could be used in the treatment of cancer too.

There has been some interest in using antibodies with drugs or irradiation attached to target therapy at the site of a tumour. However, Dr Glennie and colleagues are using unmodified antibodies alone - these are often referred to as "naked mAbs". What interests the Southampton researchers is why some naked mAbs are highly effective in killing cancer cells whilst others are not.

The traditional thinking on how mAbs exert their effect is that they alert the body to danger and recruit immune cells to the site of the tumour. However, Dr Glennie now has evidence which suggests that the successful mAbs are the ones which can trigger a change in the cancer cells themselves. These mAbs tell the cancer cells to stop growing or even to commit suicide (a process known as programmed cell death). Thus the mAbs are restoring the very control mechanism thought to have gone wrong in cancer.

Dr Glennie and Professor George Stevenson (also at Southampton) have developed a mAb which recognises a molecule (CD20) found on the surface of B cells. They are using this in trials with patients with a type of cancer called transplant lymphoma. This cancer affects approximately 3% of patients who have had an organ transplant as a side-effect of the immunosuppressive drugs they need to take.

So far the mAb has been given to nine patients and Dr Glennie describes the results as "very impressive". The antibodies destroy all the patient's B cells, both cancerous and healthy. However healthy B cells return when all the mAb has gone from the patient's body, approximately 6 months after treatment. Surprisingly the patients seem to manage very well without their normal B cells!

Advances in antibody engineering and production means that the cost of making mAbs is falling rapidly, so that large-scale application is now economically viable. The prospects look good for a therapy that should be without the unpleasant side-effects of current cancer treatments.


Story Source:

The above story is based on materials provided by British Society Of Immunologists. Note: Materials may be edited for content and length.


Cite This Page:

British Society Of Immunologists. "Monoclonal Antibodies -- The Gentle Cure For Cancer?." ScienceDaily. ScienceDaily, 2 December 1997. <www.sciencedaily.com/releases/1997/12/971202072503.htm>.
British Society Of Immunologists. (1997, December 2). Monoclonal Antibodies -- The Gentle Cure For Cancer?. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/1997/12/971202072503.htm
British Society Of Immunologists. "Monoclonal Antibodies -- The Gentle Cure For Cancer?." ScienceDaily. www.sciencedaily.com/releases/1997/12/971202072503.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins